Biopharmaceutical News Week 48 2014
Management Shake-up in Pharma
This was a month a major management shake-up. End of October Sanofi announced that it had ousted Chris Viehbacher. Earlier this week news came that Ulf Wiinberg, CEO of Lundbeck, resigned from his position because of a breach of company’s code conduct. Then Takeda announced the departure of Doug Cole, the US President of the Japanese company. And a few days later Novo Nordisk indicated that it shrinked its executive team, as Executive Vice-President Lise Kingo, in charge of human resources and corporate communication, was making an exit.
November 30, 2014
GlaxoSmithKline is planning a major reorganization
GlaxoSmithKline (GSK) is supposed to announce a major workforce restructuring that will include hundreds of job cuts, in particular in the US, where sales are flagging.
Acquisitions /Mergers/Joint-ventures
November 26, 2014
BioMarin makes a $680 million bid for Prosensa
BioMarin Pharmaceutical, located in California, has made a proposal to buy Prosensa of the Netherlands for $680 million in cash. BioMarin is mainly involved in developing products for rare diseases. Prosensa’s Duchenne muscular dystrophy product (DMD) drisapersen, is currently under review at the US Food and Drug Administration. If drisapersen obtains approval in the US no later than 15 May 2016, and approval in Europe no later than 15 February 2017, two milestone payment of about $80 million will be paid to Prosensa.
Business
November 22, 2014
LabCorp and CareDx stop their on partnership on lupus test
LabCorp and CareDx have stopped their collaboration to develop a lupus flare predictor test after completing the first phase of their study.
Illumina and bioMérieux are developing an innovative sequencing system for infectious diseases
Illumina is entering a four years collaboration with French diagnostic company bioMerieux to develop a next-generation sequencing (NGS) system that can identify infection bacteria in hospital settings and service laboratories.
November 27, 2014
Glaxo stops a development deal with Dynavax
GlaxoSmithKline does not exercise its option to license Dynavax's DV1179, an investigational bifunctional inhibitor of toll-like receptors (TLR) 7 and 9, after it failed to meet its expected endpoints.
Approval of drugs
November 25, 2014
European Commission approves Lilly diabetes drug Trulicity
The European Commission has approved Trulicity (dulaglutide) from Eli Lilly, a once-weekly glucagon-like peptide-1 receptor agonist, in combination with other diabetes treatments and as monotherapy for the treatment of type 2 diabetes. Trucility will have to compete with AstraZeneca’s Bydureon and GlaxoSmithKline’s Eperzan.
European Commission approves Boehringer Ingelheim for lung cancer
The Europe's Committee for Medicinal Products for Human Use (CHMP) approves Boehringer Ingelheim's Vargatef (nintedanib), in combination with docetaxel, for the treatment of non-small cell lung cancer (NSCLC). Nintedanib is an oral pan-angiokinase inhibitor which inhibits endothelial growth factor receptors (VEGFR), platelet derived growth factor receptors (PDGFR) and fibroblast growth factor receptors (FGFR) signalling pathways. Earlier this month, the Europe's Committee has adopted a positive opinion supporting approval of nintedanib, for the treatment of ideopathic pulmonary fibrosis (IPF). A few months ago, the FDA has already approved the drug, branded as Ofev, for the IPF indication in the United States.
Drugs at clinical stage
November 25, 2014
Phase 3 brodalumab psoriasis trial successful
Amgen and partner AstraZeneca announce that the Amagine-2 Phase 3 trial evaluating two doses of brodalumab, in patients with moderate-to-severe plaque psoriasis, met its primary endpoints at week 12.
Ebola
November 26, 2014
Experimental Ebola vaccine from GSK and NIH appears safe in early test
An experimental Ebola vaccine from GlaxoSmithKline and the National Institutes of Health (NIH) was well tolerated and produced an immune response in all 20 healthy volunteers who received it. The results were published in the New England Journal of Medicine.
Merck acquires rights to NewLink's Ebola vaccine candidate
Merck enters into an exclusive worldwide license agreement with NewLink Genetics to develop and commercialize investigational rVSV-EBOV (Ebola) vaccine candidate. The vaccine was created by scientists at the Public Health Agency of Canada's National Microbiology Laboratory.
Technology
November 23, 2014
A 'hybrid vehicle' that delivers DNA
A new hybrid vehicle, under development, based on a small part of a microbe’s genes, gives DNA vaccines new potential.
Miscellaneous
November 23, 2014
AstraZeneca invests $200M to expand US biologics site
AstraZeneca has announced plans to expand its US biologics manufacturing centre in Frederick, Maryland, spending more than $200 million to increase production in support of its "maturing pipeline". The company says the investment will help it keep pace “with a growing demand for the development and use of biologics, which currently represent nearly 50% of AstraZeneca’s overall pipeline”. The expansion, which should be complete in 2017, will add 40,000 square feet of manufacturing, laboratory and administrative space and bring 300 new jobs to the site.
November 28, 2014
Italian drug regulator suspends two batches of Novartis flu vaccine after deaths
After the sudden death of three patient who received Novartis' Fluad influenza vaccine, Italy's drug regulator AIFA suspends two lots of the product.
Author : Jean-Claude MULLER, Special Advisor,Innovation & International Relationship (I&IR)
Discover our services in Marketing & Business Development:
See All News
See other Biopharmaceutical News
see other Pharma & Biotech events in 2014
Last News
- Alzheimer’s disease : Beyond the beta amyloid hypothesis
- Un monde posteuropéen : déjà une réalité ?
- PIB, Budget, Dépenses : Une mise au point.
Events
News archives
- February 2025
- January 2025
- December 2024
- November 2024
- October 2024
- September 2024
- August 2024
- July 2024
- June 2024
- March 2024
- February 2024
- January 2024
- November 2023
- September 2023
- July 2023
- April 2023
- March 2023
- January 2023
- December 2022
- November 2022
- October 2022
- August 2022
- June 2022
- May 2022
- April 2022
- March 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- October 2018
- June 2018
- May 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- September 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- June 2014
- May 2014
- April 2014
- March 2014
- January 2014
- November 2013
- September 2013
- July 2013
- May 2013
- April 2013
- March 2013
- January 2013
- December 2012
- November 2012
- October 2012
- March 2012